NDANASALSPRAY
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
NEFFY (epinephrine) by ARS Pharmaceuticals is adrenergic alpha-agonists [moa]. First approved in 2024.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEFFY is a nasal spray formulation of epinephrine, an alpha-adrenergic agonist approved by the FDA in August 2024. It is indicated for emergency treatment of anaphylaxis, leveraging a novel intranasal delivery route to provide rapid systemic epinephrine absorption. This represents an innovative alternative to traditional intramuscular epinephrine auto-injectors.
Growth12.6 years to LOE
Early-stage growth product with no established competitors; commercial teams are building market infrastructure and launch momentum in a nascent category.
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Started May 2026
446 enrolled
Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Started Sep 2025
30 enrolled
Distributive ShockHemodynamic AssessmentCritical Illness
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Started May 2025
600 enrolled
Allergic Reactions
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Started May 2025
238 enrolled
Hypotension During Surgery
Worked on NEFFY at ARS Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.